Method for detecting urine fibronectin, and kit thereof

A technology of fibronectin and urine, which is applied in the field of medical testing, can solve problems such as low willingness for self-discipline inspection, influence of operator's technical level, unstandardized use methods, etc., and achieve good economic benefits, good social and economic benefits , the effect of reducing the economic burden

Inactive Publication Date: 2013-01-30
沈周俊 +2
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The "NMP22BladderChek Test" test paper launched in 2008 is a product successfully developed by Invillis Medical Diagnostics Group. It is a product protected by foreign patents. It is expensive and not suitable for the wide application of Chinese people.
At present, the clinical detection of FN still has the following problems: 1. The method of use ha...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for detecting urine fibronectin, and kit thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] like figure 1 Shown:

[0045] A method for detecting urinary fibronectin, the operation steps are as follows:

[0046] Detection principle:

[0047] The content of fibronectin (FN) in human urine was determined by enzyme-linked immunosorbent assay. The pre-coated FN in the microtiter plate and the FN in the urine are competitively combined with the FN antibody. After adding the enzyme-labeled antibody, an antigen-antibody complex is formed. The colorimetry is performed at a wavelength of 492nm, and the FN content and OD value in the urine are to be determined. (492nm) is directly proportional.

[0048] Specimen collection:

[0049] Take the first morning urine. When collecting urine, instruct the patient to abstain from water after 10:00 p.m. the night before. After the urine sample is centrifuged at 3,000r / min for 10 minutes, the supernatant is collected and placed in a clean container at 2-8°C. It can be stored for 48 hours, and can be stored for 1 month at -20°C. ...

Embodiment 2

[0066] Patients with transitional epithelial carcinoma of the bladder at different stages, patients with benign urinary tract diseases (group A without urinary tract infection, group B with urinary tract infection), renal cell carcinoma, hamartoma and adrenocortical tumor (group c) , non-urinary system malignant tumor (group D) patients and normal control group urine crossing, serum fibronectin FN concentration.

[0067] Except for 5 patients with BTCC, samples were collected before operation and 10-16 days after operation, and samples were collected before operation for other patients. Take the morning urine or more than 2 small pairs of urine in the bladder from the patients and normal controls, centrifuge at 2,000r / min for 10min, draw the supernatant and put it in a -20℃ refrigerator. At the same time as the urine wave was collected, fasting peripheral venous blood was drawn, the serum was separated within 3 hours, and stored in a -20°C refrigerator for later use.

[0068]...

Embodiment 3

[0089] 1. Materials and Methods

[0090] 1. Clinical data

[0091] 1) Bladder cancer group: 50 cases. There were 34 males and 16 females. Aged 26-82 years old, with an average of 62 years old. The pathological types were transitional cell carcinoma of the bladder. According to the International Union Against Cancer (UICC) staging: T 1 29 cases, T 2 17 cases, T 3 4 cases. Pathological grade: G 1 18 cases, G 2 24 cases, G 3 8 cases. 50 patients with bladder cancer underwent partial cystectomy in 42 cases, laser therapy in 5 cases, and total cystectomy in 3 cases. All tumors were completely removed. Urine samples were collected from each patient before operation and 1 month after operation.

[0092] 2) Non-bladder cancer group: a total of 30 patients with other genitourinary diseases. There were 18 males and 12 females. Aged 34-76 years old, with an average of 60 years old. Among them (1) 20 cases of benign genitourinary diseases group, 12 males and 8 females aged ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a method for detecting the urine fibronectin, and a kit thereof. The method comprises the steps of specimen acquisition, experiment preparation, sample addition, incubation, plate washing, enzyme addition, incubation, washing, color development and termination. A bladder cancer diagnosis technology having the advantages of simplicity, rapidness, non-invasion, low price, high sensitivity and strong specificity is established in the invention to determine the concentrations of the urine fibronectin of a bladder cancer patient in different pathological phases, and the index of the bladder cancer infiltration degree can be discriminated through the difference of the urine fibronectin.

Description

technical field [0001] The invention belongs to the field of medical detection methods, and more particularly relates to a method for detecting urinary fibronectin and a kit for its preparation. Background technique [0002] Bladder transitional cell carcinoma (Bladder transitional cell carcinoma, BTCC. Hereinafter referred to as "bladder cancer") is the most common malignant tumor of the urinary system, and it is also one of the common malignant tumors in the whole body. But in recent years, the incidence of bladder cancer in my country's cities has been increasing year by year. Cystoscopy and urine exfoliation cytology are the main means of diagnosis and follow-up of bladder cancer at present. Cystoscopy is an invasive examination, and the examinee is often afraid; and cystoscopy has certain blind spots, making it difficult to diagnose flat low-grade bladder cancer and carcinoma in situ. Even the most advanced soft scopes have a false negative rate of 8.7% and an infecti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N33/68G01N33/531
Inventor 沈周俊钟山陆颖理
Owner 沈周俊
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap